8-K: Owlet Inc. Reports Strong Q2 2024 Results with 58% Revenue Growth and Improved Profitability

Owlet Inc. announced a strong second quarter in 2024, highlighted by a 58% year-over-year revenue increase and significant improvements in profitability.

Summary

• Owlet, Inc. reported its financial results for the second quarter of 2024, showing substantial growth and improved financial performance.
• The company's revenue reached approximately $20.7 million, a 58% increase compared to the same period last year.
• Gross margin improved to approximately 50%, up by 1,000 basis points year-over-year.
• Net loss significantly decreased to approximately ($1.1) million, an 85% improvement from the ($8.5) million loss in the prior year.
• Adjusted EBITDA was approximately $0.1 million, a significant turnaround from the ($4.3) million loss in the same quarter of the previous year.
• The company achieved CE Medical certification for the UK and Europe, enabling the launch of Dream Sock in major European markets.
• Owlet experienced record-breaking sales during Amazon Prime Day, further boosting their Q3 performance.
• For the second half of 2024, Owlet estimates net revenue to be between $37 million and $42 million, with gross margins between 46% and 50%, and an adjusted EBITDA loss of ($3) million to break-even.
• For the full year 2024, Owlet projects net revenue between $72.5 million and $77.5 million, gross margins between 47% and 49%, and an adjusted EBITDA loss between ($6) million and ($3) million.

Sentiment

Score: 8

Explanation: The document conveys a strong positive sentiment due to significant revenue growth, improved profitability, and expansion into new markets. The company's outlook is also optimistic, with a clear path to adjusted EBITDA breakeven.

Positives

• Owlet achieved a substantial 58% year-over-year revenue growth in Q2 2024.
• The company significantly improved its gross margin to approximately 50%, indicating better cost management.
• Owlet reduced its net loss by 85% year-over-year, demonstrating improved profitability.
• The company achieved positive adjusted EBITDA of $0.1 million, a major improvement from the previous year's loss.
• Owlet successfully obtained CE Medical certification for the UK and Europe, expanding its market reach.
• Record-breaking sales during Amazon Prime Day indicate strong consumer demand.
• The company is on track to achieve adjusted EBITDA breakeven by the end of 2024.

Negatives

• Owlet still reported a net loss of ($1.1) million for the quarter, although significantly improved.
• The company is still projecting an adjusted EBITDA loss for the full year 2024, although it is expected to be between ($6) million and ($3) million.

Risks

• The company's future performance is subject to regulatory approvals and actions by bodies like the FDA.
• Owlet faces competition in the market, which could impact its ability to grow profitably.
• The company's ability to obtain additional financing and manage debt obligations remains a risk.
• Economic conditions and consumer spending habits could affect Owlet's business.
• The company's ability to protect its intellectual property and maintain relationships with key stakeholders is crucial.

Future Outlook

Owlet anticipates continued growth and improved profitability, projecting net revenue between $72.5 million and $77.5 million for the full year 2024 and aiming for adjusted EBITDA breakeven by the end of the year.

Management Comments

• Kurt Workman, Owlet's CEO, stated that the company's results in the first half of 2024 give them added confidence that this year is a turning point.
• Workman also mentioned that they have delivered strong, double-digit revenue and sell-through growth.
• Workman highlighted the company's continued efforts to streamline the business, improve gross margins, and lower operating expenses.
• Workman noted the company's expansion into the UK and EU markets following FDA clearances in 2023.
• Workman expressed excitement about leading the company into the next phase of its growth.

Industry Context

This announcement reflects a positive trend for Owlet in the smart infant monitoring market, where companies are focusing on expanding their product reach and improving financial performance. The CE Medical certification and expansion into Europe are significant steps in this direction.

Comparison to Industry Standards

• Owlet's 58% year-over-year revenue growth is impressive compared to many established players in the consumer health tech space, such as Fitbit (now part of Google) which has seen more modest growth in recent years.
• The improvement in gross margin to 50% is a positive sign, putting Owlet in line with other companies in the medical device sector, such as Masimo, which typically maintain gross margins in the 50-60% range.
• The move towards adjusted EBITDA breakeven is a critical step for Owlet, as many growth-stage companies in the health tech sector struggle with profitability. Companies like Livongo (now part of Teladoc) have demonstrated the importance of achieving profitability for long-term success.
• The expansion into the UK and EU markets is a strategic move similar to that of other medical device companies, such as Medtronic, which have a global presence and benefit from diverse revenue streams.

Stakeholder Impact

• Shareholders will likely view the strong financial results and positive outlook favorably.
• Employees may be encouraged by the company's growth and improved financial stability.
• Customers will benefit from the expansion of Owlet's products and services.
• Suppliers may see increased demand for their products and services.
• Creditors may have increased confidence in the company's ability to meet its obligations.

Next Steps

• Owlet plans to continue laying the regulatory groundwork for additional commercial expansion in the US and abroad.
• The company will focus on further streamlining its business to achieve improved gross margins and lower operating expenses.
• Owlet will continue to develop software and digital data solutions to bridge the healthcare gap between hospital and home.

Key Dates

Keywords

Owlet, infant monitoring, Dream Sock, financial results, revenue growth, gross margin, EBITDA, net loss, CE Medical certification, Amazon Prime Day